At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 944 enrolled
Drug / intervention
acetylcysteine +1 moredrug
Likely dose
acetylcysteine 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: a Prospective, Randomized, Double-blind, Placebo-controlled Trial
In Brief
A Phase 3 clinical trial evaluating acetylcysteine and Placebo for Rhinosinusitis. Completed, enrolled 944 participants across 37 sites in 4 countries.
Detailed Summary
The trial was conducted as a prospective, randomized, multinational, multicenter, double-blind study in 4 parallel groups of patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinosinusitis
CountriesBulgaria, Germany, Moldova, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartOct 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedOct 10, 2019
Enrollment StartOct 22, 2020
Primary CompletionApr 20, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.7 years ago
Interventions
acetylcysteinedrug
600 mg tablet
Placebodrug
Placebo to acetylcysteine